Cargando…
Immunohistochemistry for Prostate Biopsy—Impact on Histological Prostate Cancer Diagnoses and Clinical Decision Making
Background: To test the value of immunohistochemistry (IHC) staining in prostate biopsies for changes in biopsy results and its impact on treatment decision-making. Methods: Between January 2017–June 2020, all patients undergoing prostate biopsies were identified and evaluated regarding additional I...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8293248/ https://www.ncbi.nlm.nih.gov/pubmed/34207594 http://dx.doi.org/10.3390/curroncol28030197 |
_version_ | 1783724994346352640 |
---|---|
author | Mandel, Philipp Wenzel, Mike Hoeh, Benedikt Welte, Maria N. Preisser, Felix Inam, Tahir Wittler, Clarissa Humke, Clara Köllermann, Jens Wild, Peter Würnschimmel, Christoph Tilki, Derya Graefen, Markus Kluth, Luis A. Karakiewicz, Pierre I. Chun, Felix K.-H. Becker, Andreas |
author_facet | Mandel, Philipp Wenzel, Mike Hoeh, Benedikt Welte, Maria N. Preisser, Felix Inam, Tahir Wittler, Clarissa Humke, Clara Köllermann, Jens Wild, Peter Würnschimmel, Christoph Tilki, Derya Graefen, Markus Kluth, Luis A. Karakiewicz, Pierre I. Chun, Felix K.-H. Becker, Andreas |
author_sort | Mandel, Philipp |
collection | PubMed |
description | Background: To test the value of immunohistochemistry (IHC) staining in prostate biopsies for changes in biopsy results and its impact on treatment decision-making. Methods: Between January 2017–June 2020, all patients undergoing prostate biopsies were identified and evaluated regarding additional IHC staining for diagnostic purpose. Final pathologic results after radical prostatectomy (RP) were analyzed regarding the effect of IHC at biopsy. Results: Of 606 biopsies, 350 (58.7%) received additional IHC staining. Of those, prostate cancer (PCa) was found in 208 patients (59.4%); while in 142 patients (40.6%), PCa could be ruled out through IHC. IHC patients harbored significantly more often Gleason 6 in biopsy (p < 0.01) and less suspicious baseline characteristics than patients without IHC. Of 185 patients with positive IHC and PCa detection, IHC led to a change in biopsy results in 81 (43.8%) patients. Of these patients with changes in biopsy results due to IHC, 42 (51.9%) underwent RP with 59.5% harboring ≥pT3 and/or Gleason 7–10. Conclusions: Patients with IHC stains had less suspicious characteristics than patients without IHC. Moreover, in patients with positive IHC and PCa detection, a change in biopsy results was observed in >40%. Patients with changes in biopsy results partly underwent RP, in which 60% harbored significant PCa. |
format | Online Article Text |
id | pubmed-8293248 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-82932482021-07-22 Immunohistochemistry for Prostate Biopsy—Impact on Histological Prostate Cancer Diagnoses and Clinical Decision Making Mandel, Philipp Wenzel, Mike Hoeh, Benedikt Welte, Maria N. Preisser, Felix Inam, Tahir Wittler, Clarissa Humke, Clara Köllermann, Jens Wild, Peter Würnschimmel, Christoph Tilki, Derya Graefen, Markus Kluth, Luis A. Karakiewicz, Pierre I. Chun, Felix K.-H. Becker, Andreas Curr Oncol Article Background: To test the value of immunohistochemistry (IHC) staining in prostate biopsies for changes in biopsy results and its impact on treatment decision-making. Methods: Between January 2017–June 2020, all patients undergoing prostate biopsies were identified and evaluated regarding additional IHC staining for diagnostic purpose. Final pathologic results after radical prostatectomy (RP) were analyzed regarding the effect of IHC at biopsy. Results: Of 606 biopsies, 350 (58.7%) received additional IHC staining. Of those, prostate cancer (PCa) was found in 208 patients (59.4%); while in 142 patients (40.6%), PCa could be ruled out through IHC. IHC patients harbored significantly more often Gleason 6 in biopsy (p < 0.01) and less suspicious baseline characteristics than patients without IHC. Of 185 patients with positive IHC and PCa detection, IHC led to a change in biopsy results in 81 (43.8%) patients. Of these patients with changes in biopsy results due to IHC, 42 (51.9%) underwent RP with 59.5% harboring ≥pT3 and/or Gleason 7–10. Conclusions: Patients with IHC stains had less suspicious characteristics than patients without IHC. Moreover, in patients with positive IHC and PCa detection, a change in biopsy results was observed in >40%. Patients with changes in biopsy results partly underwent RP, in which 60% harbored significant PCa. MDPI 2021-06-09 /pmc/articles/PMC8293248/ /pubmed/34207594 http://dx.doi.org/10.3390/curroncol28030197 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Mandel, Philipp Wenzel, Mike Hoeh, Benedikt Welte, Maria N. Preisser, Felix Inam, Tahir Wittler, Clarissa Humke, Clara Köllermann, Jens Wild, Peter Würnschimmel, Christoph Tilki, Derya Graefen, Markus Kluth, Luis A. Karakiewicz, Pierre I. Chun, Felix K.-H. Becker, Andreas Immunohistochemistry for Prostate Biopsy—Impact on Histological Prostate Cancer Diagnoses and Clinical Decision Making |
title | Immunohistochemistry for Prostate Biopsy—Impact on Histological Prostate Cancer Diagnoses and Clinical Decision Making |
title_full | Immunohistochemistry for Prostate Biopsy—Impact on Histological Prostate Cancer Diagnoses and Clinical Decision Making |
title_fullStr | Immunohistochemistry for Prostate Biopsy—Impact on Histological Prostate Cancer Diagnoses and Clinical Decision Making |
title_full_unstemmed | Immunohistochemistry for Prostate Biopsy—Impact on Histological Prostate Cancer Diagnoses and Clinical Decision Making |
title_short | Immunohistochemistry for Prostate Biopsy—Impact on Histological Prostate Cancer Diagnoses and Clinical Decision Making |
title_sort | immunohistochemistry for prostate biopsy—impact on histological prostate cancer diagnoses and clinical decision making |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8293248/ https://www.ncbi.nlm.nih.gov/pubmed/34207594 http://dx.doi.org/10.3390/curroncol28030197 |
work_keys_str_mv | AT mandelphilipp immunohistochemistryforprostatebiopsyimpactonhistologicalprostatecancerdiagnosesandclinicaldecisionmaking AT wenzelmike immunohistochemistryforprostatebiopsyimpactonhistologicalprostatecancerdiagnosesandclinicaldecisionmaking AT hoehbenedikt immunohistochemistryforprostatebiopsyimpactonhistologicalprostatecancerdiagnosesandclinicaldecisionmaking AT weltemarian immunohistochemistryforprostatebiopsyimpactonhistologicalprostatecancerdiagnosesandclinicaldecisionmaking AT preisserfelix immunohistochemistryforprostatebiopsyimpactonhistologicalprostatecancerdiagnosesandclinicaldecisionmaking AT inamtahir immunohistochemistryforprostatebiopsyimpactonhistologicalprostatecancerdiagnosesandclinicaldecisionmaking AT wittlerclarissa immunohistochemistryforprostatebiopsyimpactonhistologicalprostatecancerdiagnosesandclinicaldecisionmaking AT humkeclara immunohistochemistryforprostatebiopsyimpactonhistologicalprostatecancerdiagnosesandclinicaldecisionmaking AT kollermannjens immunohistochemistryforprostatebiopsyimpactonhistologicalprostatecancerdiagnosesandclinicaldecisionmaking AT wildpeter immunohistochemistryforprostatebiopsyimpactonhistologicalprostatecancerdiagnosesandclinicaldecisionmaking AT wurnschimmelchristoph immunohistochemistryforprostatebiopsyimpactonhistologicalprostatecancerdiagnosesandclinicaldecisionmaking AT tilkiderya immunohistochemistryforprostatebiopsyimpactonhistologicalprostatecancerdiagnosesandclinicaldecisionmaking AT graefenmarkus immunohistochemistryforprostatebiopsyimpactonhistologicalprostatecancerdiagnosesandclinicaldecisionmaking AT kluthluisa immunohistochemistryforprostatebiopsyimpactonhistologicalprostatecancerdiagnosesandclinicaldecisionmaking AT karakiewiczpierrei immunohistochemistryforprostatebiopsyimpactonhistologicalprostatecancerdiagnosesandclinicaldecisionmaking AT chunfelixkh immunohistochemistryforprostatebiopsyimpactonhistologicalprostatecancerdiagnosesandclinicaldecisionmaking AT beckerandreas immunohistochemistryforprostatebiopsyimpactonhistologicalprostatecancerdiagnosesandclinicaldecisionmaking |